GlassScriptPhysician profile
Veena Rajashekhar
NPI 1356342612
$6,960.36
in general payments reported to CMS, 2019-2025
23 companies · $630 in 2025
The $630 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,233 · 2020: $941 · 2021: $1,483 · 2022: $1,340 · 2023: $155 · 2024: $178 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,068.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $857.41 | 2019-2022 | |
| Genzyme Corporation | $809.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $530.03 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $418.58 | 2019-2025 | Xolair |
| Biohaven Pharmaceuticals, INC. | $253.36 | 2020-2021 | |
| Blueprint Medicines Corporation | $248.07 | 2023-2025 | Ayvakit |
| Alk-Abello, INC | $218.74 | 2019-2022 | |
| Amgen INC. | $194.62 | 2022 | |
| Pfizer INC. | $186.42 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $156.31 | 2019-2021 | |
| Galderma Laboratories, L.P. | $136.40 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $135.68 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $124.98 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $119.58 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $105.53 | 2019 | |
| Aimmune Therapeutics, INC. | $76.27 | 2020-2021 | |
| Kaleo, INC. | $67.12 | 2020 | |
| Philips North America LLC | $62.48 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.60 | 2024 | |
| Greer Laboratories, INC. | $47.93 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.12 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Rajashekhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.